Folder zelmac
•
0 likes•337 views
Tegaserod is a 6 mg tablet used to treat abdominal pain and constipation associated with irritable bowel syndrome in female patients. It works by stimulating gastrointestinal motility. It should be taken twice daily before meals for up to 12 weeks. Common side effects include diarrhea. Caution is required in patients with liver or kidney impairment.
Report
Share
Report
Share
Download to read offline
Recommended
A zelmac a4
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after organic causes have been ruled out. Common side effects include diarrhea. Caution is required in patients with impaired renal or hepatic function or a history of recurrent diarrhea.
C zelmac a4
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after ruling out an organic cause through appropriate testing. Common side effects include diarrhea. Caution is required in patients with renal or hepatic impairment or a history of recurrent diarrhea.
Aliment pharmacol ther_mueller_lissner_2001
Tegaserod, a 5-HT4 receptor partial agonist, provided rapid and sustained relief of abdominal pain, bloating, and constipation associated with irritable bowel syndrome (IBS) in a 12-week randomized controlled trial. Tegaserod at doses of 2 mg and 6 mg twice daily significantly improved overall IBS symptoms and individual symptoms like abdominal pain and discomfort, number of bowel movements, and stool consistency compared to placebo. Tegaserod was well tolerated with only transient diarrhea occurring more frequently than placebo. The study demonstrates that tegaserod offers effective relief of multiple IBS symptoms.
Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patien...
Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patien...PVI, PeerView Institute for Medical Education
Chair, Donna H. Ryan, MD, FTOS, prepared useful Practice Aids pertaining to obesity management for this CME activity titled “Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patient-Centered Approach to Overcoming Barriers and Addressing Underlying Causes of Obesity.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/3qWzNTq. CME credit will be available until July 14, 2022.
Gall bladder
1. The document summarizes the medical history, diagnosis, treatment, and follow up care for a 45-year-old female patient admitted to the hospital with right upper abdominal pain and vomiting who was diagnosed with acute calcular cholecystitis.
2. She underwent a cholecystectomy after admission and was given various medications including antibiotics, analgesics, dextrose, and vitamins during her 10-day hospital stay.
3. Upon discharge, she was prescribed augmentin, tramadol, and omeprazole to continue treatment and prevent stress gastritis following the surgery.
SGLT2 Endocrine CME Grand Rounds Final
SGLT2 inhibitors lower blood glucose by reducing glucose reabsorption in the kidney. Three SGLT2 inhibitors have been approved by the FDA to treat type 2 diabetes: canagliflozin, dapagliflozin, and empagliflozin. They have similar mechanisms of action and efficacy outcomes, lowering A1c by 0.5-1% and fasting plasma glucose by 15-40 mg/dL on average. Side effects include increased urinary tract and genital infections as well as volume depletion related side effects. SGLT2 inhibitors provide an additional treatment option for type 2 diabetes through their insulin-independent mechanism of action.
Jardiance- PresentationCopy
Jardiance (empagliflozin) is an FDA-approved SGLT-2 inhibitor for the treatment of type 2 diabetes. It works by inhibiting SGLT2 in the kidney to increase glucose excretion. A 104-week randomized controlled trial found that Jardiance as an add-on to metformin was as effective as glimepiride in reducing A1C levels and had fewer side effects like weight gain and hypoglycemia. The study concluded that Jardiance can be considered as a second-line treatment for patients with uncontrolled diabetes on metformin, especially those who are obese or hypertensive. However, more research is still needed to fully understand its cardiovascular effects.
B a4 zelmac
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after ruling out an organic cause through appropriate testing. Common side effects include diarrhea. Caution is required in patients with impaired renal or hepatic function or a history of recurrent diarrhea.
Recommended
A zelmac a4
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after organic causes have been ruled out. Common side effects include diarrhea. Caution is required in patients with impaired renal or hepatic function or a history of recurrent diarrhea.
C zelmac a4
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after ruling out an organic cause through appropriate testing. Common side effects include diarrhea. Caution is required in patients with renal or hepatic impairment or a history of recurrent diarrhea.
Aliment pharmacol ther_mueller_lissner_2001
Tegaserod, a 5-HT4 receptor partial agonist, provided rapid and sustained relief of abdominal pain, bloating, and constipation associated with irritable bowel syndrome (IBS) in a 12-week randomized controlled trial. Tegaserod at doses of 2 mg and 6 mg twice daily significantly improved overall IBS symptoms and individual symptoms like abdominal pain and discomfort, number of bowel movements, and stool consistency compared to placebo. Tegaserod was well tolerated with only transient diarrhea occurring more frequently than placebo. The study demonstrates that tegaserod offers effective relief of multiple IBS symptoms.
Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patien...
Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patien...PVI, PeerView Institute for Medical Education
Chair, Donna H. Ryan, MD, FTOS, prepared useful Practice Aids pertaining to obesity management for this CME activity titled “Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patient-Centered Approach to Overcoming Barriers and Addressing Underlying Causes of Obesity.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/3qWzNTq. CME credit will be available until July 14, 2022.
Gall bladder
1. The document summarizes the medical history, diagnosis, treatment, and follow up care for a 45-year-old female patient admitted to the hospital with right upper abdominal pain and vomiting who was diagnosed with acute calcular cholecystitis.
2. She underwent a cholecystectomy after admission and was given various medications including antibiotics, analgesics, dextrose, and vitamins during her 10-day hospital stay.
3. Upon discharge, she was prescribed augmentin, tramadol, and omeprazole to continue treatment and prevent stress gastritis following the surgery.
SGLT2 Endocrine CME Grand Rounds Final
SGLT2 inhibitors lower blood glucose by reducing glucose reabsorption in the kidney. Three SGLT2 inhibitors have been approved by the FDA to treat type 2 diabetes: canagliflozin, dapagliflozin, and empagliflozin. They have similar mechanisms of action and efficacy outcomes, lowering A1c by 0.5-1% and fasting plasma glucose by 15-40 mg/dL on average. Side effects include increased urinary tract and genital infections as well as volume depletion related side effects. SGLT2 inhibitors provide an additional treatment option for type 2 diabetes through their insulin-independent mechanism of action.
Jardiance- PresentationCopy
Jardiance (empagliflozin) is an FDA-approved SGLT-2 inhibitor for the treatment of type 2 diabetes. It works by inhibiting SGLT2 in the kidney to increase glucose excretion. A 104-week randomized controlled trial found that Jardiance as an add-on to metformin was as effective as glimepiride in reducing A1C levels and had fewer side effects like weight gain and hypoglycemia. The study concluded that Jardiance can be considered as a second-line treatment for patients with uncontrolled diabetes on metformin, especially those who are obese or hypertensive. However, more research is still needed to fully understand its cardiovascular effects.
B a4 zelmac
Zelmac is a 6 mg tablet containing tegaserod hydrogen maleate indicated for symptomatic treatment of abdominal pain and constipation associated with irritable bowel syndrome in female patients. It should be taken twice daily prior to meals for up to 12 weeks after ruling out an organic cause through appropriate testing. Common side effects include diarrhea. Caution is required in patients with impaired renal or hepatic function or a history of recurrent diarrhea.
Long term safety_apt_oct02
This study evaluated the long-term safety of tegaserod, a 5-hydroxytryptamine-4 receptor partial agonist used to treat constipation-predominant irritable bowel syndrome, in 579 patients over 12 months. The most common adverse events related to tegaserod were mild and transient diarrhea, headache, abdominal pain, and flatulence. The study found that tegaserod appeared to be well tolerated for long-term use with no unexpected safety issues identified.
Novick b358 apt_nov02
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of tegaserod in treating female patients with irritable bowel syndrome characterized by abdominal pain/discomfort and constipation. 1519 women were randomized to receive either tegaserod 6 mg twice daily or placebo for 12 weeks. The primary outcome was the Subject's Global Assessment of Relief, which assessed overall symptom relief. Secondary outcomes included assessments of abdominal pain, bowel habits, and bloating. Results showed tegaserod produced statistically significant improvements in the primary and secondary outcomes compared to placebo. The most common side effect was diarrhea, but this led to discontinuation in only 1.6% of patients receiving tegaserod. Therefore
Megestrol Acetate
This document discusses megestrol acetate, including its members, forms, mechanism of action, dosing, administration, safety considerations, and key drug interactions. It lists 12 team members who will discuss megestrol acetate's introduction, brand names, pricing, mechanism of action, dosing, pharmacokinetics, safety issues, and other important details. The document provides an overview of megestrol acetate and the topics the team plans to cover in their discussion.
Tega
1) The document is a prescribing information sheet for Zelnorm (tegaserod maleate) tablets that describes the drug's clinical pharmacology and results from clinical studies on its use for treating irritable bowel syndrome with constipation and chronic idiopathic constipation.
2) Clinical trials showed that treatment with Zelnorm resulted in a greater proportion of patients achieving relief of IBS symptoms compared to placebo, as well as an increase in bowel movements.
3) Studies in patients under 65 with chronic idiopathic constipation found that a higher percentage of those treated with Zelnorm experienced an increase of at least 1 complete spontaneous bowel movement per week compared to placebo.
ocp.ppt
This document describes various hormonal contraceptive options, including their mechanisms of action, effectiveness, side effects, and appropriate patients. It discusses oral contraceptives containing different estrogen and progestin combinations, the contraceptive patch, injectables, rings, implants, and IUDs. It provides details on the benefits and risks of each method as well as contraindications. Emerging extended cycle oral contraceptives and a new subcutaneous injectable are also mentioned.
Current Trends in Management of Gastroesophageal Reflux Disease
The document discusses prevalence rates of gastroesophageal reflux disease (GERD) around the world, ranging from 7.4-22% depending on the region. It then provides information on the pathophysiology of GERD, including abnormal lower esophageal sphincter function and increases in abdominal pressure. The clinical manifestations of GERD are described as well as different phenotypic presentations such as nonerosive reflux disease, erosive esophagitis, and Barrett's esophagus. Diagnostic approaches and management strategies for GERD are summarized based on guidelines from the American College of Gastroenterology and World Gastroenterology Organization. Proton pump inhibitors are described as first-line treatment options for G
New anti epileptic drugs
Levetiracetam is a broad-spectrum newer antiepileptic drug approved in 1999. It has fewer drug interactions than older AEDs due to simpler pharmacokinetics without enzyme induction. Its unique mechanism of action involves synaptic vesicle protein SV2A. Common adverse effects are mild and reversible. Lacosamide approved in 2008 is indicated as adjunctive therapy for focal seizures. It is initiated at 50mg twice daily and increased weekly by 100mg with a maximum of 400mg daily due to potential CNS and gastrointestinal side effects.
Material, Vincent M.(Drug Study in GastroIntestinal System)-converted.pdf
The document provides drug study information on the antiulcer medications lansoprazole (Prevacid), cimetidine (Tagamet HB), and famotidine (Pepcid). It includes sections on the generic and brand names, classifications, mechanisms of action, indications, contraindications, adverse reactions, dosages, and nursing considerations for each drug. The document was submitted by a nursing student as part of the requirements for a pharmacology course to their clinical instructor.
Gerd by Dr.Reda Emam Amer
This document discusses GERD (gastroesophageal reflux disease). It provides an overview of GERD including a classification system, symptoms, diagnostic tests like pH monitoring, and subtypes such as erosive esophagitis. Alarm symptoms that may indicate complications are noted. Causes, pathophysiology, and treatment options for various subtypes are reviewed including proton pump inhibitors, prokinetic drugs, treatments for refractory GERD, and the relationship between H. pylori infection and GERD. Newer formulations and potential future treatments are also mentioned.
Ibs
Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain or discomfort associated with changes in bowel habits. Common symptoms include abdominal discomfort relieved with defecation, changes in stool frequency or form. Treatment depends on whether constipation or diarrhea predominates, and may include increased fiber, bulk forming laxatives, antispasmodics, or anti-inflammatory drugs. While the cause is unknown, theories include altered stress responses, low-grade inflammation, and changes in gut microbiota. Diet modifications and lifestyle changes can help manage symptoms.
Sulfad trial germany 2012
This document summarizes the results of a randomized, prospective, open-label clinical trial evaluating the efficacy and safety of Sulfad tablets for the management of non-alcoholic steatohepatitis (NASH) patients. The trial involved 100 patients taking Sulfad tablets for 3 months. Significant improvements were seen in liver enzymes and lipid profiles after 1, 2, and 3 months of treatment. No major safety issues were reported. The study concluded that Sulfad tablets were well-tolerated and effective for the management of NASH patients.
Sulfad trial germany 2012
efficacy and safety of Sulfad tablets in the management of NASH
patients: A randomized ,prospective, open label, multi-center,
controlled, phase III clinical trial.
Nursing Education: Appetite Stimulants for Elderly Patients
A handout I formulated to bolster nursing education during an internship/Advanced Pharmacy Practice Experience (APPE) in medication safety at a hospital.
Case study on peptic ulcer disease
This case study presents a 3-year old female patient admitted with fever, coffee ground vomiting and abdominal pain. She had a history of upper respiratory infection and allergy to cephalosporin and amoxicillin. Endoscopy revealed a non-bleeding gastric ulcer. Laboratory tests showed signs of anemia and inflammation. She was diagnosed with NSAIDs-induced peptic ulcer disease. Her treatment plan included cefotaxime, paracetamol, esomeprazole, and pantoprazole. She was discharged after 2 days with counseling on diet, medication use, and follow up.
Ranitidine 150mg film coated tablets smpc- taj pharmaceuticals
Ranitidine Taj Pharma : Uses, Side Effects, Interactions, Pictures, Warnings, Ranitidine Dosage & Rx Info | Ranitidine Uses, Side Effects -: Indications, Side Effects, Warnings, Ranitidine - Drug Information - Taj Pharma, Ranitidine dose Taj pharmaceuticals Ranitidine interactions, Taj Pharmaceutical Ranitidine contraindications, Ranitidine price, Ranitidine Taj Pharma Ranitidine 150mg Film-coated TabletsSMPC- Taj Pharma . Stay connected to all updated on Ranitidine Taj Pharmaceuticals Taj pharmaceuticals Hyderabad.
Rabeprazole 20mg gastro resistant tablets smpc- taj pharmaceuticals
Rabeprazole Taj Pharma : Uses, Side Effects, Interactions, Pictures, Warnings, Rabeprazole Dosage & Rx Info | Rabeprazole Uses, Side Effects -: Indications, Side Effects, Warnings, Rabeprazole - Drug Information - Taj Pharma, Rabeprazole dose Taj pharmaceuticals Rabeprazole interactions, Taj Pharmaceutical Rabeprazole contraindications, Rabeprazole price, Rabeprazole Taj Pharma Rabeprazole 20mg Gastro-resistant Tablets SMPC- Taj Pharma . Stay connected to all updated on Rabeprazole Taj Pharmaceuticals Taj pharmaceuticals Hyderabad.
Penis ed- management
This document provides an overview of the nonsurgical and surgical management of erectile dysfunction. It discusses lifestyle changes, medications, oral therapies, injections, vacuum devices, and penile prosthetics. It provides details on various oral phosphodiesterase type-5 inhibitors, hormonal therapies, herbal supplements and their effectiveness. Risks, benefits, dosages and administration techniques are described for different treatment options. Surgical implantation of penile prosthetics is discussed as a last option for treatment.
Endometriosis : Dilemma with drugs
Presentation given in 2018 on Endometriosis - management in the infertility setting. When are assisted reproductive technologies used and what are the medications used for dealing with this condition?
Prostate cancer Integrative Approaches
This document summarizes a presentation about prostate cancer nutrition for prevention of recurrence and progression. It discusses the naturopathic doctor's background working with prostate cancer patients. It then covers lifestyle interventions like exercise, stress reduction, and dietary strategies focused on a plant-based diet low in fat and androgens to slow disease progression. Specific foods highlighted for their prostate health benefits include soy isoflavones, lycopene from tomatoes, and glucosinolates from broccoli.
Zee ppt gerd
GERD is a common condition where stomach acid refluxes into the esophagus, potentially causing symptoms like heartburn and damage to the esophagus. About 44% of adults experience heartburn monthly, with risk factors including obesity, smoking, and hiatal hernia. Diagnosis involves assessing symptoms, and testing may include pH monitoring or endoscopy. Treatment focuses on lifestyle changes and medications like PPIs to reduce acid production, while complications can include esophagitis, strictures, and Barrett's esophagus, a precursor to esophageal cancer. Surgery is an option for severe cases that do not respond to medical management.
Aum profile
Alissa Universal Motors is a commercial vehicle supplier with a vision to be recognized as a leading supplier backed by outstanding after-sales services. Their mission is to be the preferred provider of high quality cargo transportation solutions where employees, customers, suppliers and shareholders are partners in their success. Their culture emphasizes integrity, transparency, responsibility, discipline, respect and being customer-oriented through teamwork, excellence and accuracy.
Aum presentation
Alissa Universal Motors Co. Ltd (AUM) is a new automotive company established in January 2009 that holds the franchise for Isuzu vehicles within the Alissa Group. AUM was created to have a stronger focus on the Isuzu business and to improve growth, decision-making, and efficiency. It is majority owned by the Alissa Group and has facilities across Saudi Arabia for sales, service, parts, and vehicle storage. AUM works closely with sister companies for financing, rentals, and aftersales support. The next steps are to finalize the dealer agreement with Isuzu Motors to officially register AUM and participate in government tenders.
More Related Content
Similar to Folder zelmac
Long term safety_apt_oct02
This study evaluated the long-term safety of tegaserod, a 5-hydroxytryptamine-4 receptor partial agonist used to treat constipation-predominant irritable bowel syndrome, in 579 patients over 12 months. The most common adverse events related to tegaserod were mild and transient diarrhea, headache, abdominal pain, and flatulence. The study found that tegaserod appeared to be well tolerated for long-term use with no unexpected safety issues identified.
Novick b358 apt_nov02
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of tegaserod in treating female patients with irritable bowel syndrome characterized by abdominal pain/discomfort and constipation. 1519 women were randomized to receive either tegaserod 6 mg twice daily or placebo for 12 weeks. The primary outcome was the Subject's Global Assessment of Relief, which assessed overall symptom relief. Secondary outcomes included assessments of abdominal pain, bowel habits, and bloating. Results showed tegaserod produced statistically significant improvements in the primary and secondary outcomes compared to placebo. The most common side effect was diarrhea, but this led to discontinuation in only 1.6% of patients receiving tegaserod. Therefore
Megestrol Acetate
This document discusses megestrol acetate, including its members, forms, mechanism of action, dosing, administration, safety considerations, and key drug interactions. It lists 12 team members who will discuss megestrol acetate's introduction, brand names, pricing, mechanism of action, dosing, pharmacokinetics, safety issues, and other important details. The document provides an overview of megestrol acetate and the topics the team plans to cover in their discussion.
Tega
1) The document is a prescribing information sheet for Zelnorm (tegaserod maleate) tablets that describes the drug's clinical pharmacology and results from clinical studies on its use for treating irritable bowel syndrome with constipation and chronic idiopathic constipation.
2) Clinical trials showed that treatment with Zelnorm resulted in a greater proportion of patients achieving relief of IBS symptoms compared to placebo, as well as an increase in bowel movements.
3) Studies in patients under 65 with chronic idiopathic constipation found that a higher percentage of those treated with Zelnorm experienced an increase of at least 1 complete spontaneous bowel movement per week compared to placebo.
ocp.ppt
This document describes various hormonal contraceptive options, including their mechanisms of action, effectiveness, side effects, and appropriate patients. It discusses oral contraceptives containing different estrogen and progestin combinations, the contraceptive patch, injectables, rings, implants, and IUDs. It provides details on the benefits and risks of each method as well as contraindications. Emerging extended cycle oral contraceptives and a new subcutaneous injectable are also mentioned.
Current Trends in Management of Gastroesophageal Reflux Disease
The document discusses prevalence rates of gastroesophageal reflux disease (GERD) around the world, ranging from 7.4-22% depending on the region. It then provides information on the pathophysiology of GERD, including abnormal lower esophageal sphincter function and increases in abdominal pressure. The clinical manifestations of GERD are described as well as different phenotypic presentations such as nonerosive reflux disease, erosive esophagitis, and Barrett's esophagus. Diagnostic approaches and management strategies for GERD are summarized based on guidelines from the American College of Gastroenterology and World Gastroenterology Organization. Proton pump inhibitors are described as first-line treatment options for G
New anti epileptic drugs
Levetiracetam is a broad-spectrum newer antiepileptic drug approved in 1999. It has fewer drug interactions than older AEDs due to simpler pharmacokinetics without enzyme induction. Its unique mechanism of action involves synaptic vesicle protein SV2A. Common adverse effects are mild and reversible. Lacosamide approved in 2008 is indicated as adjunctive therapy for focal seizures. It is initiated at 50mg twice daily and increased weekly by 100mg with a maximum of 400mg daily due to potential CNS and gastrointestinal side effects.
Material, Vincent M.(Drug Study in GastroIntestinal System)-converted.pdf
The document provides drug study information on the antiulcer medications lansoprazole (Prevacid), cimetidine (Tagamet HB), and famotidine (Pepcid). It includes sections on the generic and brand names, classifications, mechanisms of action, indications, contraindications, adverse reactions, dosages, and nursing considerations for each drug. The document was submitted by a nursing student as part of the requirements for a pharmacology course to their clinical instructor.
Gerd by Dr.Reda Emam Amer
This document discusses GERD (gastroesophageal reflux disease). It provides an overview of GERD including a classification system, symptoms, diagnostic tests like pH monitoring, and subtypes such as erosive esophagitis. Alarm symptoms that may indicate complications are noted. Causes, pathophysiology, and treatment options for various subtypes are reviewed including proton pump inhibitors, prokinetic drugs, treatments for refractory GERD, and the relationship between H. pylori infection and GERD. Newer formulations and potential future treatments are also mentioned.
Ibs
Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain or discomfort associated with changes in bowel habits. Common symptoms include abdominal discomfort relieved with defecation, changes in stool frequency or form. Treatment depends on whether constipation or diarrhea predominates, and may include increased fiber, bulk forming laxatives, antispasmodics, or anti-inflammatory drugs. While the cause is unknown, theories include altered stress responses, low-grade inflammation, and changes in gut microbiota. Diet modifications and lifestyle changes can help manage symptoms.
Sulfad trial germany 2012
This document summarizes the results of a randomized, prospective, open-label clinical trial evaluating the efficacy and safety of Sulfad tablets for the management of non-alcoholic steatohepatitis (NASH) patients. The trial involved 100 patients taking Sulfad tablets for 3 months. Significant improvements were seen in liver enzymes and lipid profiles after 1, 2, and 3 months of treatment. No major safety issues were reported. The study concluded that Sulfad tablets were well-tolerated and effective for the management of NASH patients.
Sulfad trial germany 2012
efficacy and safety of Sulfad tablets in the management of NASH
patients: A randomized ,prospective, open label, multi-center,
controlled, phase III clinical trial.
Nursing Education: Appetite Stimulants for Elderly Patients
A handout I formulated to bolster nursing education during an internship/Advanced Pharmacy Practice Experience (APPE) in medication safety at a hospital.
Case study on peptic ulcer disease
This case study presents a 3-year old female patient admitted with fever, coffee ground vomiting and abdominal pain. She had a history of upper respiratory infection and allergy to cephalosporin and amoxicillin. Endoscopy revealed a non-bleeding gastric ulcer. Laboratory tests showed signs of anemia and inflammation. She was diagnosed with NSAIDs-induced peptic ulcer disease. Her treatment plan included cefotaxime, paracetamol, esomeprazole, and pantoprazole. She was discharged after 2 days with counseling on diet, medication use, and follow up.
Ranitidine 150mg film coated tablets smpc- taj pharmaceuticals
Ranitidine Taj Pharma : Uses, Side Effects, Interactions, Pictures, Warnings, Ranitidine Dosage & Rx Info | Ranitidine Uses, Side Effects -: Indications, Side Effects, Warnings, Ranitidine - Drug Information - Taj Pharma, Ranitidine dose Taj pharmaceuticals Ranitidine interactions, Taj Pharmaceutical Ranitidine contraindications, Ranitidine price, Ranitidine Taj Pharma Ranitidine 150mg Film-coated TabletsSMPC- Taj Pharma . Stay connected to all updated on Ranitidine Taj Pharmaceuticals Taj pharmaceuticals Hyderabad.
Rabeprazole 20mg gastro resistant tablets smpc- taj pharmaceuticals
Rabeprazole Taj Pharma : Uses, Side Effects, Interactions, Pictures, Warnings, Rabeprazole Dosage & Rx Info | Rabeprazole Uses, Side Effects -: Indications, Side Effects, Warnings, Rabeprazole - Drug Information - Taj Pharma, Rabeprazole dose Taj pharmaceuticals Rabeprazole interactions, Taj Pharmaceutical Rabeprazole contraindications, Rabeprazole price, Rabeprazole Taj Pharma Rabeprazole 20mg Gastro-resistant Tablets SMPC- Taj Pharma . Stay connected to all updated on Rabeprazole Taj Pharmaceuticals Taj pharmaceuticals Hyderabad.
Penis ed- management
This document provides an overview of the nonsurgical and surgical management of erectile dysfunction. It discusses lifestyle changes, medications, oral therapies, injections, vacuum devices, and penile prosthetics. It provides details on various oral phosphodiesterase type-5 inhibitors, hormonal therapies, herbal supplements and their effectiveness. Risks, benefits, dosages and administration techniques are described for different treatment options. Surgical implantation of penile prosthetics is discussed as a last option for treatment.
Endometriosis : Dilemma with drugs
Presentation given in 2018 on Endometriosis - management in the infertility setting. When are assisted reproductive technologies used and what are the medications used for dealing with this condition?
Prostate cancer Integrative Approaches
This document summarizes a presentation about prostate cancer nutrition for prevention of recurrence and progression. It discusses the naturopathic doctor's background working with prostate cancer patients. It then covers lifestyle interventions like exercise, stress reduction, and dietary strategies focused on a plant-based diet low in fat and androgens to slow disease progression. Specific foods highlighted for their prostate health benefits include soy isoflavones, lycopene from tomatoes, and glucosinolates from broccoli.
Zee ppt gerd
GERD is a common condition where stomach acid refluxes into the esophagus, potentially causing symptoms like heartburn and damage to the esophagus. About 44% of adults experience heartburn monthly, with risk factors including obesity, smoking, and hiatal hernia. Diagnosis involves assessing symptoms, and testing may include pH monitoring or endoscopy. Treatment focuses on lifestyle changes and medications like PPIs to reduce acid production, while complications can include esophagitis, strictures, and Barrett's esophagus, a precursor to esophageal cancer. Surgery is an option for severe cases that do not respond to medical management.
Similar to Folder zelmac (20)
Current Trends in Management of Gastroesophageal Reflux Disease
Current Trends in Management of Gastroesophageal Reflux Disease
Material, Vincent M.(Drug Study in GastroIntestinal System)-converted.pdf
Material, Vincent M.(Drug Study in GastroIntestinal System)-converted.pdf
Nursing Education: Appetite Stimulants for Elderly Patients
Nursing Education: Appetite Stimulants for Elderly Patients
Ranitidine 150mg film coated tablets smpc- taj pharmaceuticals
Ranitidine 150mg film coated tablets smpc- taj pharmaceuticals
Rabeprazole 20mg gastro resistant tablets smpc- taj pharmaceuticals
Rabeprazole 20mg gastro resistant tablets smpc- taj pharmaceuticals
More from haithamo
Aum profile
Alissa Universal Motors is a commercial vehicle supplier with a vision to be recognized as a leading supplier backed by outstanding after-sales services. Their mission is to be the preferred provider of high quality cargo transportation solutions where employees, customers, suppliers and shareholders are partners in their success. Their culture emphasizes integrity, transparency, responsibility, discipline, respect and being customer-oriented through teamwork, excellence and accuracy.
Aum presentation
Alissa Universal Motors Co. Ltd (AUM) is a new automotive company established in January 2009 that holds the franchise for Isuzu vehicles within the Alissa Group. AUM was created to have a stronger focus on the Isuzu business and to improve growth, decision-making, and efficiency. It is majority owned by the Alissa Group and has facilities across Saudi Arabia for sales, service, parts, and vehicle storage. AUM works closely with sister companies for financing, rentals, and aftersales support. The next steps are to finalize the dealer agreement with Isuzu Motors to officially register AUM and participate in government tenders.
Aum presentation dealers meeting
This document summarizes AUM Marketing Activities for an Isuzu Dealers Conference. It outlines AUM's vision, mission, values around integrity, teamwork, discipline, customer focus and excellence. It describes AUM facilities including showrooms and workshops. It then summarizes past and planned marketing activities for 2010, including CRM activation, retail campaigns, an AUM support center training program, and a special financing campaign with Arab National Bank.
Aum profile
Alissa Universal Motors is a commercial vehicle supplier with a vision to be recognized as a leading supplier backed by outstanding after-sales services. Their mission is to be the preferred provider of high quality cargo transportation solutions where employees, customers, suppliers and shareholders are partners in their success. Their culture emphasizes integrity, transparency, responsibility, discipline, respect and being customer-oriented through teamwork, excellence and accuracy.
Bubble image for suv market ksa 20100805
This document contains information about SUV vehicle prices, horsepower specifications, and volumes for various models from Toyota, Nissan, Mitsubishi and other manufacturers. It includes two bubble charts showing SUV pricing compared to horsepower and volume for both 4x2 and 4x4 drive models. Accompanying tables provide the base prices, engine sizes and horsepower for SUVs like the Fortuner, RAV4, Pathfinder and Pajero Sport across different grade levels. A specification definition key is also included showing the standard and optional features associated with each grade.
Feasability study
This document provides a feasibility study and summary for acquiring the Renault franchise as an exclusive dealership in Saudi Arabia. It outlines the aim to maximize profitability through business diversification and capturing the opportunity of exclusive Renault dealership. Success factors include Renault's product adaptations, quality aftersales service, and marketing support. Sales forecasts project steadily increasing volumes and market share through 2013. Financial projections show increasing profits and strong returns. Challenges around brand image, service quality, parts availability, and resale values are identified along with proposed solutions. The next steps are to obtain board approval and finalize agreements with Renault.
Feasability study wout appendix
This document provides a feasibility study for acquiring the Renault franchise as an exclusive dealership in Saudi Arabia. It includes a summary, agenda, aims and purpose, success factors, sales forecasts, financial summary, challenges and solutions. The success factors section outlines Renault's product offerings, after sales service quality, marketing support, and Alissa's strengths. The financial summary projects profit, return on capital employed, and balance sheets. Challenges around brand image, service, parts availability and resale value are addressed. The next steps are to obtain board approval and finalize the dealer agreement with Renault.
Aum profile
Alissa Universal Motors is a commercial vehicle supplier with a vision to be recognized as a leading supplier backed by outstanding after-sales services. Their mission is to be the preferred provider of high quality cargo transportation solutions where employees, customers, suppliers and shareholders are partners in their success. Their culture emphasizes integrity, transparency, responsibility, discipline, respect and being customer-oriented through teamwork, excellence and accuracy.
Aum presentation
Alissa Universal Motors Co. Ltd (AUM) is a new automotive company established in January 2009 that holds the franchise for Isuzu vehicles within the Alissa Group. AUM was created to have a stronger focus on the Isuzu business and to improve growth, decision-making, and efficiency. It is majority owned by the Alissa Group and has facilities across Saudi Arabia for sales, service, parts, and vehicle storage. AUM works closely with sister companies for financing, rentals, and aftersales support. The next steps are to finalize the dealer agreement with Isuzu Motors to officially register AUM and participate in government tenders.
Aum marketing plan overview 2010 in thailand
The document outlines Alissa Universal Motors' (AUM) marketing plan for 2010. The objectives are to establish AUM as the leader in commercial vehicles and services, achieve 54% market share in the central region, and activate the CRM system. The plan details 2010 targets, organization structure, customer database development, quarterly marketing activities and events, fleet customer activities, press activities, gifts, promotional materials, website development, and training. The key events include a family offers campaign, 25 years celebration, and test drive events.
Alissa group profile
The document provides an overview of the Abdullatif Alissa Group, a Saudi automotive and investment conglomerate. It discusses the group's history beginning in 1940, its operating companies including automotive dealerships and financing, and its investment portfolio spanning various industries. The group has a presence across Saudi Arabia and has established strategic alliances. It believes its partnerships position it for above-market growth as the Saudi automotive market continues its strong potential for expansion.
Suv
The document provides an overview and proposal for introducing the Isuzu SUV in the Saudi Arabian market. It begins with background on Alissa Group, the automotive group proposing the partnership. It then analyzes the strong and growing Saudi SUV market, dominated by Japanese brands. Forecasts show potential for Isuzu SUV sales to gain a 28% market share within 5 years. Competitor analyses and specifications are provided for the Pathfinder and other top SUV models. The proposal recommends a strategy to introduce and promote the Isuzu SUV through Alissa Group's existing sales, financing, rental, and service channels.
July 10 sales analasis (2)
- Sales year-to-date in June 2010 were up significantly compared to the same period in 2009 across most vehicle brands, with the largest increases seen in KIA (+87%) and GM (+61%).
- BBC-Jeddah and Al Yemni (Central) were the top-selling Isuzu dealers in Saudi Arabia in July and year-to-date based on market share percentages provided.
- The D-Max and N-Series models led Isuzu vehicle sales in July, with BBC-Jeddah the top-selling dealer for both lines.
July 10 sales analasis
The document summarizes Isuzu's third quarter 2010 business review meeting. It shows that year-to-date sales through June 2010 increased significantly over the same period in 2009 for most car models. It also provides details on sales contributions and market shares of different Isuzu dealers in Saudi Arabia for June and July. The document outlines upcoming launches of the new D-Max family vehicles and recaps achievements in Saudi Build sales competitions.
Hyundai meeting
Alissa Group is presenting to Hyundai about potential business opportunities in Saudi Arabia. Alissa has over 60 years of automotive experience in Saudi Arabia working with brands like GM, Isuzu, and Yellow Hat. They are now the 3rd largest GM dealer in the Middle East. Alissa is proposing to partner with Hyundai to expand their commercial vehicle sales given the strong growth forecast for the automotive market and commercial vehicles in Saudi Arabia. Alissa believes a strategic alliance would deliver mutual benefits by leveraging their experience and Hyundai's brand in the promising Saudi automotive sector.
Geely introduction presentation
Alissa Group is a Saudi automotive company with over 60 years of experience. It holds franchises for GM, Isuzu, and other brands. The meeting agenda explores business opportunities between Alissa and Geely Motors in the GCC automotive sector. Alissa has a large portfolio of automotive assets and dealerships across Saudi Arabia, with a workforce of 3,000 and over $1 billion in assets. It seeks to expand its partnerships with international brands to capitalize on the strong growth prospects in the Saudi automotive market.
Tata meeting
Alissa presented to Hyundai on future business opportunities in Saudi Arabia's automotive sector. Alissa has over 60 years of experience partnering with international brands in Saudi Arabia. It currently holds franchises for GM, Isuzu, and Yellow Hat, and owns various automotive companies including a multi-brand retailer, financing company, and rental and leasing company. Alissa sees the Saudi automotive market growing strongly in the coming years and believes a strategic alliance with Hyundai could deliver mutual benefits by capitalizing on this market growth.
Renault feasibility study summary for presentation
This document provides a feasibility study for acquiring a Renault franchise dealership in Saudi Arabia. It outlines the aims to maximize profitability and business diversification. Key success factors include Renault's product range and marketing support, as well as Alissa's sales network and experience. Financial forecasts project increasing net profits and returns. Challenges around brand image, service quality, parts availability and resale values could be addressed through marketing and partnership with Renault. The proposal is to obtain approval and finalize an exclusive dealer agreement with Renault.
Renault feasibility study summary detailed
This feasibility study evaluates acquiring the exclusive Renault dealership in KSA. Key points include:
- Renault has a small market share but growing product lines and a marketing strategy is proposed to reposition the brand.
- The KSA auto market is growing, especially in subcompact and compact segments. Acquiring Renault could capitalize on opportunities in growing segments.
- An analysis of Renault's past performance is presented along with sales forecasts projecting market share growth over five years if the dealership is acquired.
- Challenges like Renault's brand image are addressed with solutions like re-launch marketing activities. Financials and an organization chart are included.
Renault board presentation
The document provides an analysis of Renault's franchise opportunity in Saudi Arabia. It includes a market analysis noting growing small car trends, an overview of Renault's history and current product range, and a proposed future product range for the GCC market. It also outlines Renault's global strategy and support for the GCC region, and results from a task force analyzing the potential for a Renault franchise in Saudi Arabia. In conclusion, the document appears to analyze the viability of a Renault franchise in the Saudi Arabian market.
More from haithamo (20)
Renault feasibility study summary for presentation
Renault feasibility study summary for presentation
Folder zelmac
- 4. ZELMAC® 6 mg tablets Presentation: Tegaserod. Tablets: 6 mg tegaserod as hydrogen maleate. Indications/Potential uses: Symptomatic treatment of female patients with abdominal pain and constipation associated with irritable bowel syndrome. An organ- ic origin of such symptoms must be ruled out by means of appropriate investigations. Dosage: 6 mg twice daily prior to a meal for a maximum of 12 weeks. Contraindications: Hypersensitivity to tegaserod hydrogen maleate and/or to any of the excipients. Precautions: Diarrhoea and/or patients with recurrent diarrhoea associated with IBS. Caution is required in patients in whom increased gastrointestinal motility could have negative effects. Use of Zelmac cannot be recommended in patients with severe hepatic impairment or severe renal failure. Caution is required in patients with mild to moderately severe renal or hepatic failure. Interactions: No drug interactions of clinical relevance. Adverse reactions: The overall incidence of adverse events in clinical trials was comparable with that of placebo, with excep- tion of diarrhoea. Packs and prices: Country-specific. Note: Before prescribing, please read full product information. References: 1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2002;97 (suppl):S1-S27. 2. Data on file, Annotated Package insert. a Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. 3. Schmitt C, et al. The 5HT4 partial agonist, tegaserord, a partial 5H4 agonist improves abdominal/pain and altered bowel function in irritable bowel syndrome. Gut 1999;45 (Suppl.V):A260 4. Muller-Lissner SA, et al. Tegaserod , a 5 HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001,15:1655-1666 5. Novick J, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16:1877-1888 ZELDF01/04ME+Ae